Table 3. MiRNAs involved in other pathways responsible for resistance of NSCLC cells to CDDP.
| miRNA Migr. / Inv. / Met. | Targets | Cells / Tissue | Expression | Function | Reference |
|---|---|---|---|---|---|
| miR-17 family (20a, 20b) | TGFßR2 | A549/CDDP | down | TGFßR2 suppressor, reverses CDDP-resistance and suppresses metastases | [81] |
| miR-21 | PTEN | Serum, NSCLC cells | up | Promotes migration, invasion and metastasis | [9] |
| mir-26b | PTEN | NSCLC tissue, NSCLC cells | down | Regulates NSCLC migration and CDDP-chemosensitivity | [78] |
| miR-27a | RKIP | A549/CDDP | up | Regulates EM-transition and CDDP-resistance | [82] |
| miR-98 | PAK1 | NSCLC tissue, A549/PAR | down | Inversely regulates PAK1, inhibits migration and invasion | [51] |
| miR-182 | PDCD4 | A549 cells | up | Induces resistance to CDDP by targeting PDCD4 | [84] |
| miR-200c | n. d. | NSCLC cell lines (n=9) | down | Inversely correlates with aggressive, invasive and chemoresistant phenotype | [8] |
| miR-206 | MET | NSCLC tissue, A549/CDDP, H1299/CDDP | down | Inhibits CDDP-resistance via MET dependent PI3K/AKT/mTOR pathways | [80] |
| miR-217 | KRAS | NSCLC tissue, A549/PAR | down | Inhibits proliferation, migration and invasion, promotes apoptosis and sensitivity to CDDP | [79] |
| DNA damage response | |||||
| miR-17/miR-92 families | TGFßR2, CDKN1A, RAD21 | A549/CDDP | down | Influence CDDP-resistance by synergistic and combined regulation of their target genes | [127] |
| miR-33b-3p | P21WAF1 | A549/CDDP | up | Impairs the DNA damage response | [128] |
| miR-92 | |||||
| miR-138 | ERCC1 | A549/CDDP | up | Negatively regulates ERCC1 expression | [38] |
| miR-155 | APAF-1 | NSCLC tissue, A549/PAR | up | Inhibits sensitivity to CDDP via negative regulation of Apaf-1 | [37] |
| miR-509-3-5p | PLK1 | CDDP-treated A549/PAR | down | Tumor suppressor, causes aberrant mitosis and anti-proliferative effects by suppressing PLK1 | [20] |
| miR-630 | ATM, H2AX, p53 | A549/PAR CDDP-treated | up | Blocks DNA-damage response | [13] |
| Drug uptake | |||||
| miR-15b | PEBP4 | A549/CDDP, NSCLC tissue | up | Suppresses PEBP4 expression and contribute to CDDP-resistance | [129] |
| miR-31-p | Dicer | A549 cells | n. d. | Enhances sensitivity to CDDP by repressing Dicer | [130] |
| miR-34a | PEBP4, MYCN | A549/PAR | up | Modulates CDDP-sensitivity in NSCLC cells by regulating PEBP4 expression | [131] |
| miR-106a | ABCA1 | A549/CDDP | up | Induces CDDP-resistance by targeting ABCA1 and inhibiting apoptosis | [68] |
| miR-148b | DNMT1 | A549/CDDP, SPC-A1/CDDP | down | Influence CDDP-sensitivity, cell viability and apoptosis | [57] |
| miR-181a | PTEN | A549/CDDP | up | Regulates epithelial-mesenchymal transition and metastatic properties of NSCLC cells | [46] |
| miR-185-5p | ABCC1 | A549/CDDP | down | Promotes CDDP-induced apoptosis by suppressing ABCC1 | [69] |
| miR-495 | ATP7A | NSCLC tissue, A549/CDDP | down | Negatively regulates ATP7A and modulates CDDP-induced apoptosis | [70] |
| miR-503 | FANCA | NSCLC tissue, A549/CDDP | down | Regulates CDDP-resistance by targeting FANCA | [102] |
n. d., not defined; Expression = expression in CDDP-resistant cells or NSCLC tissue in comparison to sensitive cells or non-malignant lung tissue.